These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 25064084)
21. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436 [TBL] [Abstract][Full Text] [Related]
22. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Turner HE; Thornton-Jones VA; Wass JA Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918 [TBL] [Abstract][Full Text] [Related]
23. [Treatment of Blue Rubber Bled Nevus syndrome with subcutaneous octreotide: a case report]. López Centeno B; Sanz Marquez S; Pérez Encinas M Farm Hosp; 2015 Nov; 39(6):402-4. PubMed ID: 26618384 [No Abstract] [Full Text] [Related]
24. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Plöckinger U; Quabbe HJ Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331 [TBL] [Abstract][Full Text] [Related]
25. Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update. Arregger AL; Cardoso EM; Sandoval OB; Monardes Tumilasci EG; Sanchez R; Contreras LN Am J Ther; 2014; 21(4):e110-6. PubMed ID: 22820717 [TBL] [Abstract][Full Text] [Related]
26. Acromegaly caused by a growth hormone-releasing hormone secreting carcinoid tumour of the lung: the effect of octreotide treatment. de Jager CM; de Heide LJ; van den Berg G; Wolthuis A; van Schelven WD Neth J Med; 2007; 65(7):263-6. PubMed ID: 17656813 [TBL] [Abstract][Full Text] [Related]
27. Octreotide for acromegaly treatment: a reappraisal. Giustina A; Karamouzis I; Patelli I; Mazziotti G Expert Opin Pharmacother; 2013 Dec; 14(17):2433-47. PubMed ID: 24124691 [TBL] [Abstract][Full Text] [Related]
28. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436 [TBL] [Abstract][Full Text] [Related]
29. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment. Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081 [No Abstract] [Full Text] [Related]
31. A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema. Shah SM; Nguyen QD; Mir HS; Polito A; Hafiz G; Tatlipinar S; Do DV; Vitale S; Haller JA Retina; 2010 Jan; 30(1):160-6. PubMed ID: 20061906 [TBL] [Abstract][Full Text] [Related]
32. Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections. Lo CH; Ho CL; Shih YL QJM; 2014 Feb; 107(2):157-8. PubMed ID: 23389434 [No Abstract] [Full Text] [Related]
33. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. Chieffo C; Cook D; Xiang Q; Frohman LA J Clin Endocrinol Metab; 2013 Oct; 98(10):4047-54. PubMed ID: 23969184 [TBL] [Abstract][Full Text] [Related]
35. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J; Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254 [TBL] [Abstract][Full Text] [Related]
36. Treatment of metastatic carcinoid tumours with octreotide. Ozbey N Int J Clin Pract; 2002 Jun; 56(5):407. PubMed ID: 12137455 [No Abstract] [Full Text] [Related]
37. Is octreotide useful for hepatic metastases due to non-neuroendocrine primary tumors? Kiki PG; Nikos E; Ioannis S; Vassilis K Clin Oncol (R Coll Radiol); 2002 Aug; 14(4):330-1. PubMed ID: 12206649 [No Abstract] [Full Text] [Related]
38. Octreotide dependency and headache: a case report. May A; Lederbogen S; Diener HC Cephalalgia; 1994 Aug; 14(4):303-4. PubMed ID: 7954762 [TBL] [Abstract][Full Text] [Related]
39. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. Kim S; Hosoya K; Takagi S; Okumura M J Am Anim Hosp Assoc; 2015; 51(6):407-12. PubMed ID: 26535461 [TBL] [Abstract][Full Text] [Related]
40. [Insulinoma effectively controlled with low dose of octreotide acetate]. Fukuoka K; Matsushita M; Murase T; Yamamori I Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2786-8. PubMed ID: 18203414 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]